Search by
Industry
Department

The Present and Future of SPL & PIM

The US Food and Drug Administration already requires that submissions for human health prescription drugs be in Structured Product Labeling (SPL) format. It is widely expected that those requirements will soon be expanded to include animal health drugs, biologics and OTC products -- most likely in that order and perhaps as soon as this year. What's more, this development could soon extend beyond the pharma industry, as 2008 could also usher in SPL requirements for medical device registrations.


Meantime, manufacturers selling their products in Europe should be thinking about how to handle Product Information Management (PIM) filings with the EMEA. Though not yet mandatory, leading pharma companies are already looking at how best to prepare their PIM submissions and associated content life cycle management. This audio conference will provide the latest information on requirements for SPL and PIM - where things stand, and where they are headed.


This audio conference covers:


  • FDA requirements and guidance regarding SPL submissions
  • How best to handle the life cycle management of your SPLs
  • What's coming next for SPL?
  • The latest information on EMEA and PIM
  • How to prepare for PIM submissions, including product information harmonization, translation needs and content life cycle management


About the speakers:


Mark Bayer is Vice President of Business Development for Reed Technology (www.ReedTech.com), providing a wide array of information management services to the pharmaceutical industry and the U.S. government. Mark oversees Reed Tech's Business Development and Pharma Operations team, who are jointly responsible for providing pharma customers with high quality SPL and PIM conversion and related services. Mark holds a B.A. degree in Mathematics from Hobart College in Geneva, NY.


Gary Saner is the Technical Manager of Reed Tech's pharmaceutical SPL and PIM services. He has 24 years of experience in software development, process management and document conversion solutions. He led the successful planning and implementation of Reed Tech's SPL conversion and related services. He has experience managing the conversion process for over 2,500 XML SPL and SPL-PLR labels to date. He has frequent contact with Reed Tech's pharma customers to understand their needs and develop solutions for them. He closely monitors the regulatory environment and is an active member of the HL7 SPL Working Group-Technical and Process Teams, Generics and eLIST sub-teams, and participates in the Veterinary Drug Interest Group (VDIG) and RPS teams. He holds a B.S. degree in Mechanical Engineering from LeTourneau University on Longview, TX with graduate studies in statistics at Villanova University.


Who should attend?


  • Regulatory Affairs & Operations
  • Documentation Managers
  • Labeling
  • Submissions Specialists
  • Product Information Managers
  • IT/IS


This audio conference is rated General Interest.

Speaker & Time

Mark Bayer & Gary Saner, Reed Technology & Information Services
The Present and Future of SPL & PIM
Title: VP Business Development & Technical Manager
Duration: 60 minutes
Discount: Buy 2 items, get 25% off your order using coupon code FX25%OFF
Event Type: Previously recorded on 2008-03-06
Item #: ac20080610
6 Mar 2008 
Registration Price:
$249.00

Order Info

Select Order Type:  
Include Transcript With Order?:  
Quantity
More
Less
 
 
Bookmark and Share reviews

Reviews

Average Rating: (based on 1 review)

Showing 1 Review:

by Karen Grant
The Present and Future of SPL & PIM
Rate this item
Similar Events
The "Why" and "How" of eCTD Conversions
Gina Ross, Beckloff Associates a Cardinal Health Company
More about The "Why" and "How" of eCTD Conversions


Managing the Shift to Electronic Submissions
Gina Ross, Beckloff Associates a Cardinal Health Company
More about Managing the Shift to Electronic Submissions


More about Using SPL for Electronic Drug Establishment Registration & Drug Listing Submissions

 
Recently Viewed
Leveraging Clinical Development Opportunities in India
Dr. Nermeen Varawalla, PRA International
More about Leveraging Clinical Development Opportunities in India


More about Good Auditing Practices for EU Notified Body Audits


Industry Update on Centralized Procedure in the EU
Dr. Ulrich Granzer, Granzer Regulatory Consulting
More about Industry Update on Centralized Procedure in the EU


Proteomics' Role in Biomarker Discovery and Validation
Dr. Daniel Chelsky, Caprion Proteomics
More about Proteomics' Role in Biomarker Discovery and Validation


More about FDA's New Enforcement Strategy: The Growing Perils of Inadequate Compliance

© Copyright 2010
ForeignExchange Translations.
All rights reserved.

Home  |   FAQ  |   Blog  |   Translation Services  |   Search  |   Privacy Policy  |   Terms of Use  |   Contact Us